In biotechnology or healthcare technology startups, demonstrating biological activity in the laboratory is just the beginning.

The real challenge lies in translating that result into a therapeutic product that can be manufactured consistently, meet regulatory requirements, integrate into clinical workflows, and ultimately reach patients.

This transition requires asking several questions from the outset:

Can the production process be standardized across batches?

Can critical quality attributes be measured and controlled?

Can the product be manufactured at a scale compatible with clinical demand?

How will variability among donors, raw materials, or manufacturing facilities be managed?

What tests will regulatory bodies require to demonstrate safety, quality, and efficacy?

Can the therapy be administered within the logistical constraints of hospitals and healthcare systems?

Does the expected clinical benefit justify the complexity and cost associated with the treatment?

And, equally important: Is there a large enough market to support development?

These considerations are often less visible than the underlying biology. Translational development isn’t simply about proving that something works.

It’s about designing from the ground up to ensure reproducibility, ease of manufacture, regulatory feasibility, and clinical adoption.

𝗜𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀, 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗽𝗲𝗻𝗱𝘀 𝗮𝘀 𝗺𝘂𝗰𝗵 𝗼𝗻 𝘁𝗵𝗲𝘀𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗮𝘀 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗶𝘁𝘀𝗲𝗹𝗳. 𝗔𝘁 𝗠𝗲𝘀𝘁𝗲𝗺𝗕𝗶𝗼, 𝘄𝗲 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗼𝗻𝗲 𝗴𝗼𝗮𝗹 𝗶𝗻 𝗺𝗶𝗻𝗱: 𝘁𝘂𝗿𝗻𝗶𝗻𝗴 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗿𝗲𝗮𝗰𝗵 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

– The Mestem Bio Team